The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.
about
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FRed cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.Coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm.How I treat essential thrombocythemia.The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosisBCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience.European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).Anagrelide: 20 years later.Experimental therapeutics for patients with myeloproliferative neoplasias.Treatment options for essential thrombocythemia and polycythemia vera.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Myelofibrosis 2012: it's complicated.WHO classification of myeloproliferative neoplasms (MPN): A critical update.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Rethinking the diagnostic criteria of polycythemia vera.European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature.Prostatic metastases and polycythemia vera on bone magnetic resonance imaging: A case report.Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.From anemia to polycythemia in 4 weeks.Highlights of 2008 in bone marrow biopsy pathology.Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasmsThe JAK2 gene as a protagonist in chronic myeloproliferative neoplasms.Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutationsHistopathological evaluation of the bone marrow in refractory anemia with ring sideroblasts and thrombocytosis associated to the JAK2-V617F mutationJAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit).Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360?5 - Reply.[Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].
P2860
Q26772881-617C02AD-7896-44A3-BBED-B05946B6D7AFQ26795666-5FC806C4-7EA5-4C42-A3F3-B165EE3E6F8AQ33401757-EE4E46B1-7A8C-4C01-BBD9-AFC8C55DC2A9Q34200436-863EB940-36DB-4159-B18C-774C8D331565Q35132271-28D54C9E-E451-4005-A4D3-B74FD65E35FDQ35433005-6FF4EEC1-30C2-47C4-AB7A-6E57FEFD64E4Q35532006-2C5D7C48-2B2A-463F-A369-02EAC4836CC6Q35695726-662A7EDD-9C56-4C86-9134-9CD1DB61DA64Q35705470-A5D3411F-BAD6-4A19-B3FC-3E3BC0DC0512Q35794415-4280C0E8-4D45-4294-88DB-2F0A096688F0Q36765086-C0B9E930-41EF-4BC4-9C57-AAF9F4B15656Q37163590-87D005DE-0ABE-4889-99A6-691F07DCFB00Q37255020-C61E2BD2-715E-4298-AB84-A1AF68255F2BQ37357291-C8962991-BE70-411D-AC98-DC48DC66AFBCQ37797983-0F6EA734-D806-4234-AD95-8FA93804D7C0Q37810107-034D9A6D-02E6-4807-80D8-4D1A515E3C5CQ38014534-F802C3B1-11FA-4F93-A2F4-7A75DEAE6625Q38065306-544F70B6-0006-4AA8-A994-BCEA198F725CQ38087202-28B1049E-FD7B-4732-ABEC-8A50B3B05D16Q38095967-AF39FC3E-3C5E-4350-85DF-B13B95B4FC09Q38154519-71D78BC9-1FFA-407D-A6AD-F7B89DFC26CBQ38164139-721CB316-8C64-4706-AF77-61F1F3B9CFE0Q38172388-0CC0658A-395F-48A2-B7CE-214D346C8498Q38689790-CEEDDA02-FB67-4AE7-8BC7-7E13627E0547Q38939571-A5F7C03D-F4EF-408A-A4FE-175EE0210A95Q38973557-3FD836C0-1DAD-4C07-B44C-C90EF06BEB7AQ39041834-916A1130-4346-41F8-8AEA-1B1646803116Q40945373-63C47203-6902-4DE2-ADE6-8860970A91D9Q41599861-A3F8B9C5-EC2B-4CE9-AC24-45560A9BF376Q41808980-BFDF60CF-CD08-408D-B013-045AC810262DQ41911563-A4ADC354-8DCD-47AA-B3B7-A710991DA49AQ42133428-87C8859E-9459-46BC-AAA1-AD885D17E2D0Q42339242-E27C5BC3-DA7C-4339-A2C7-A0BD0D6DD87DQ42415244-AD39F0F4-DD18-475D-A452-E3CBC77B9E7CQ42532748-F9D12C90-968B-4386-8B34-632958A8DA63Q43785416-57925330-5C69-48BF-A814-712AFA3F1309Q45884600-2B65AB91-C992-4004-A30F-280BDD9C7AE8Q46636672-C4D27B03-7D0C-4EDD-95E7-7A64C8728709Q46804782-EDCF0166-2ED2-4377-8A70-58A2EE063B01Q48631037-8867E719-9572-4BCC-9513-078B15E04274
P2860
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The revised World Health Organ ...... osis: an alternative proposal.
@en
The revised World Health Organ ...... osis: an alternative proposal.
@nl
type
label
The revised World Health Organ ...... osis: an alternative proposal.
@en
The revised World Health Organ ...... osis: an alternative proposal.
@nl
prefLabel
The revised World Health Organ ...... osis: an alternative proposal.
@en
The revised World Health Organ ...... osis: an alternative proposal.
@nl
P1433
P1476
The revised World Health Organ ...... osis: an alternative proposal.
@en
P2093
Jerry L Spivak
Richard T Silver
P304
P356
10.1182/BLOOD-2007-12-128454
P407
P577
2008-04-09T00:00:00Z